

# E-PHA BINDING TO GLYCOPROTEINS FROM SERUM OF CDGS PATIENTS




1. Control
2. Type 1a--died at 6
3. Type 1a--living
4. Type 4
5. Type 1b--before mannose
6. Type 1b--after mannose

**Status:** E-PHA binding may indicate clinical severity in Type 1a patients.  
Further analyses pending.

Figure 1


A




B

E-PHA

A) Flow cytometry and B) dot-blot analyses on blood from normal and CDGS Type II patient.



**B**



**Figure 3**





Figure 4

A



B


Normal blood

Core 2 GlcNAc-T deficient mouse blood

B220

1B11

Figure 5

**B**

Normal blood



 $\alpha$ M-II-deficient mouse blood

E-PHA


Tomato Lectin

FIGURE 6

Core fucosylation of serum immunoglobulin M  
before and after initiation of fucose therapy



**Figure 7**

**FIGURE 8**






Figure 9





FIGURE 10

**Figure 11**





Figure 12

**FIGURE 13**




Figure 14




FIGURE 15







Figure 16



Figure 17



	Binding of Diagnostic Reagent	
	Normal	Glycosylation Disorder
	+	-
	-	+